Form 8-K - Current report:
SEC Accession No. 0000950170-22-011817
Filing Date
2022-06-17
Accepted
2022-06-17 16:32:55
Documents
12
Period of Report
2022-06-15
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20220615.htm   iXBRL 8-K 85482
  Complete submission text file 0000950170-22-011817.txt   207446

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220615_pre.xml EX-101.PRE 11354
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220615_lab.xml EX-101.LAB 13887
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220615.xsd EX-101.SCH 2443
6 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220615_htm.xml XML 4893
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

EIN.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 221024376
SIC: 2834 Pharmaceutical Preparations